Expression of Matrix Metalloproteinase-7 is an Unfavorable Prognostic Factor in Intrahepatic Cholangiocarcinoma

Hirashita, Teijiro; Iwashita, Yukio; Ohta, Masayuki; Komori, Yoko; Eguchi, Hidetoshi; Yada, Kazuhiro; Kitano, Seigo
April 2012
Journal of Gastrointestinal Surgery;Apr2012, Vol. 16 Issue 4, p842
Academic Journal
Background: Intrahepatic cholangiocarcinoma (IHCC) is a highly malignant neoplasm, but the prognostic factors of IHCC are not yet fully understood. The matrix metalloproteinases (MMPs) are known to be related to tumor viability. The aim of this study was to evaluate the prognostic significance of clinicopathological and immunohistochemical characteristics of resected IHCC. Patients and Methods: From 1996 to 2006, we surgically treated 35 patients with IHCC. Clinicopathological and immunohistochemical characteristics, including expression of MMPs, vascular endothelial growth factor, and epidermal growth factor receptor in the resected specimens, were investigated, and overall survival rates were evaluated with regard to the characteristics using univariate and multivariate analyses. Results: Univariate analysis revealed the significant prognostic factors to be preoperative serum CEA and CA19-9, intraoperative transfusion, tumor size, surgical margin, lymph node metastasis, invasion of portal and hepatic vein, intrahepatic metastasis, UICC stage, and expression of MMP-7. Subsequent multivariate analysis indicated that MMP-7 was an independent prognostic factor (hazard ratio (HR), 4.698; 95% confidence interval (CI), 0.057-0.866; P = 0.03) along with intrahepatic metastasis (HR, 5.694; 95% CI, 0.029-0.706; P = 0.017). Conclusion: MMP-7 expression is associated with a poor prognosis in patients with resected IHCC.


Related Articles

  • EGFR, FLT1 and Heparanase as Markers Identifying Patients at Risk of Short Survival in Cholangiocarcinoma Hoffmann, Andreas-Claudius; Goekkurt, Eray; Danenberg, Peter V.; Lehmann, Sylvia; Ehninger, Gerhard; Aust, Daniela E.; Stoehlmacher-Williams, Jan // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Background: Cholangiocarcinoma remains to be a tumor with very few treatment choices and limited prognosis. In this study, we sought to determine the prognostic role of fms-related tyrosine kinase 1/vascular endothelial growth factor receptor 1 (FLT1/VEGFR1), heparanase (HPSE) and epidermal...

  • New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the Japan Society for Gastroenterological Carcinogenesis G-Project committee. Sawada, Tetsuji; Yashiro, Masakazu; Sentani, Kazuhiro; Oue, Naohide; Yasui, Wataru; Miyazaki, Kohji; Kai, Keita; Fushida, Sachio; Fujimura, Takashi; Ohira, Masaichi; Kakeji, Yoshihiro; Natsugoe, Shoji; Shirabe, Ken; Nomura, Sachiyo; Shimada, Yutaka; Tomita, Naohiro; Hirakawa, Kosei; Maehara, Yoshihiko // Gastric Cancer;Jan2015, Vol. 18 Issue 1, p119 

    Background: The G-Project committee was erected by the Japan Society for Gastroenterological Carcinogenesis with an aim of establishing a new classification scheme based on molecular biological characteristics that would supplement the conventional TNM classification to better predict outcome....

  • Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Yoshikawa, D.; Ojima, H.; Iwasaki, M.; Hiraoka, N.; Kosuge, T.; Kasai, S.; Hirohashi, S.; Shibata, T. // British Journal of Cancer;1/29/2008, Vol. 98 Issue 2, p418 

    Epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and human epidermal growth factor receptor 2 (HER2) have been considered as potential therapeutic targets in cholangiocarcinoma, but no studies have yet clarified the clinicopathological or prognostic...

  • Clinical significance of VEGFR-2 and F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy. Sole, Claudio; Calvo, Felipe; Alvarez, Emilio; Peligros, Isabel; Garcia-Alfonso, Pilar; Ferrer, Carlos; Ochoa, Enrique; Herranz, Rafael; Carreras, Jose // European Journal of Nuclear Medicine & Molecular Imaging;Oct2013, Vol. 40 Issue 11, p1635 

    Purpose: Vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor-1 (EGFR), and cyclooxygenase-2 (COX-2) stimulate key processes involved in tumor progression and are important targets for cancer drugs. F-FDG maximum standardized uptake value (SUVmax) is a marker...

  • VEGF, VEGFR3, and PDGFRB Protein Expression Is Influenced by RAS Mutations in Medullary Thyroid Carcinoma. Mancikova, Veronika; Inglada-Pérez, Lucía; Curras-Freixes, Maria; de Cubas, Aguirre A.; Gómez, Álvaro; Letón, Rocío; Kersten, Iris; Leandro-García, Luis Javier; Comino-Méndez, Iñaki; Apellaniz-Ruiz, María; Sánchez, Lara; Cascón, Alberto; Sastre-Marcos, Julia; García, Juan F.; Rodríguez-Antona, Cristina; Robledo, Mercedes // Thyroid;Aug2014, Vol. 24 Issue 8, p1251 

    Background: Tyrosine kinase inhibitors (TKIs) have achieved remarkable clinical results in medullary thyroid carcinoma (MTC) patients. However, the considerable variability in patient response to treatment with TKIs remains largely unexplained. There is evidence that it could be due, at least in...

  • The correlation of expression of VEGF and EGFR with SUV of 18FDG-PET-CT in non-small cell lung cancer. Xiguang Liu; Hongjun Zhang; Xiaoyun Yu; Tingting Song; Peng Huang; Haichao Wang; Shan-ai Song // Contemporary Oncology / Wspolczesna Onkologia;2014, Vol. 18 Issue 5, p334 

    Aim of the study: To explore the correlation of the expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) with maximum standardised uptake value (SUVmax) of 18FDG-PET-CT in non-small cell lung cancer (NSCLC). Material and methods: Thirty patients...

  • Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice. Hurwitz, Selwyn; Zhang, Hongzheng; Yun, Sujin; Batuwangala, Thil; Steward, Michael; Holmes, Steve; Rycroft, Daniel; Pan, Lin; Tighiouart, Mourad; Shin, Hyung; Koenig, Lydia; Wang, Yuxiang; Chen, Zhuo (Georgia); Shin, Dong // Cancer Chemotherapy & Pharmacology;Mar2012, Vol. 69 Issue 3, p577 

    Purpose: DT-IgG is a fully humanized dual-target therapeutic antibody being developed to simultaneously target epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), important signaling molecules for tumor growth. The antitumor pharmacodynamics (PD) of DT-IgG was...

  • Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer. Ga-Eon Kim; Ji Shin Lee; Yoo-Duk Choi; Kyung-Hwa Lee; Jae Hyuk Lee; Jong Hee Nam; Chan Choi; Sung Sun Kim; Min Ho Park; Jung Han Yoon; Sun-Seog Kweon // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background Gene expression profiling of breast cancer has identified distinct subtypes associated with different clinical outcomes. Metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases (TIMPs) are involved in several key pathways of tumor growth, invasion and metastasis,...

  • VEGF EXPRESSION AND MICROVESSEL DENSITY IN GASTRIC CARCINOMAS. Stanculescu, Diana; Simionescu, Cristiana; Georgescu, Claudia; Margaritescu, Cl.; Muntean, Mihaela // Annals of the Romanian Society for Cell Biology;2011, Vol. 16 Issue 2, p188 

    The angiogenesis is one of the most important factors in tumor development and dissemination. We aimed to evaluate the angiogenesis and its involvement in gastric carcinomas natural history, based on immunohistochemical expression of vascular endothelial growth factor and tumor microvessel...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics